Xu Canxia, Xiao Lijun, Zou Huifang
Department of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 Sep;35(9):1000-4. doi: 10.3969/j.issn.1672-7347.2010.09.017.
To observe the effect of birid triple viable on peptic ulcer patients with Helicobacter pylori(H.pylori) infection.
A total of 120 peptic ulcer patients with H.pylori infection was randomly divided into 2 groups. The control group was treated with the triple therapy including Esomeprazole, Amoxicillin, and Furazolidone. The treatment group was treated with the same triple therapy plus birid triple viable. The pH values of the gastric juice, bacterial culture of the gastric juice, the therapy-related side effects and the healing rate of ulcer and erosive were observed before the treatment and after a 14-day-treatment respectively. The (14)C-urea breath test((14)C-UBT) was used to evaluate the H.pylori eradication rates 4 weeks after the treatment.
After the treatment, pH values of the gastric juice in both groups were significantly higher than those before the treatment (P<0.05). When pH values of the gastric juice ≥4, the positive rate of bacterial culture in the treatment group was lower than that of the control group (80.0% and 97.4% respectively, P<0.05). The rate of adverse effects in the treatment group was lower than that in the control group (11.7% and 30% respectively, P<0.05).After a 2-week treatment, the healing rate of ulcer and erosion was 80% and 68.7% in the treatment group, and 73.3% and 40.7% in the control group. The healing rate of ulcer had no significant difference in the 2 groups (P>0.05),while the healing rate of erosion in the treatment group was higher than that of the control group (P<0.05).The H.pylori eradication rates evaluated by per-protocol (PP) analysis in the treatment group was significantly higher than that of the control group (80.4% and 62.4% respectively, P<0.05).
The combined use of birid triple viable and the triple therapy of H.pylori in peptic ulcer patients with H.pylori infection can reduce the bacteria of the gastric juice and therapy-related side effects. It can increase the H.pylori eradication rate and promote the healing of erosion.
观察双歧三联活菌对幽门螺杆菌(H.pylori)感染的消化性溃疡患者的疗效。
将120例H.pylori感染的消化性溃疡患者随机分为2组。对照组采用埃索美拉唑、阿莫西林和呋喃唑酮的三联疗法治疗。治疗组在相同三联疗法基础上加用双歧三联活菌治疗。分别在治疗前及治疗14天后观察胃液pH值、胃液细菌培养、治疗相关不良反应以及溃疡和糜烂的愈合率。采用碳-14尿素呼气试验(¹⁴C-UBT)评估治疗4周后H.pylori根除率。
治疗后,两组胃液pH值均显著高于治疗前(P<0.05)。当胃液pH值≥4时,治疗组细菌培养阳性率低于对照组(分别为80.0%和97.4%,P<0.05)。治疗组不良反应发生率低于对照组(分别为11.7%和30%,P<0.05)。治疗2周后,治疗组溃疡和糜烂的愈合率分别为80%和68.7%,对照组分别为73.3%和40.7%。两组溃疡愈合率无显著差异(P>0.05),而治疗组糜烂愈合率高于对照组(P<0.05)。按符合方案(PP)分析评估,治疗组H.pylori根除率显著高于对照组(分别为80.4%和62.4%,P<0.05)。
双歧三联活菌与幽门螺杆菌三联疗法联合应用于H.pylori感染的消化性溃疡患者,可减少胃液细菌及治疗相关不良反应。可提高H.pylori根除率并促进糜烂愈合。